SecBot SecBot
SECBOTREPLAY Home › Report › IMTX

IMTX · Immatics reported full-year 2025 financial results with a significant…

https://immatics.com/ · PRESS-RELEASE filed Mar 5, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 5, 2026 at 07:00 ET

Immatics reported full-year 2025 financial results with a significant revenue decline to $56.8 million and a net loss of $230.8 million, driven by the prior year's one-time collaboration revenue. The company maintains a strong cash position of $551.4 million, extending its runway into 2028, and continues to advance its PRAME-targeted oncology pipeline with key milestones expected in 2026 and 2027, including pivotal data readouts and BLA submission for anzu-cel in melanoma.

  • Revenue declined to $56.8 million in 2025 from $183.1 million in 2024, primarily due to the absence of one-time collaboration revenue from Bristol Myers Squibb.
  • Net loss was $230.8 million in 2025 compared to a net profit of $17.9 million in 2024.
  • Cash and financial assets totaled $551.4 million as of December 31, 2025, following a $125 million public offering, supporting operations into 2028.
  • Phase 3 SUPRAME trial for anzu-cel in melanoma remains on track with interim and final analyses expected in 2026, BLA submission in 1H 2027, and commercial launch in 2H 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access